shares of Dr Reddy’s Laboratories fell as lots as 2.24 according to cent to hit intraday low of Rs three,062 after Reuters reported that an US corporation has charged India’s 2nd biggest pharma company for packaging lapses.
Reuters said that US customer Product safety fee charged the Hyderabad-primarily based drugmaker for failing to conform with policies on child-resistant packaging for five of its products.
The corporation, but, said it “firmly disagrees with the (US) government’s allegations,” and introduced it might keep cooperating with US authorities, the Reuters file added.
shares of Dr Reddy’s Labs ended 2.thirteen consistent with cent decrease at Rs 3,071.
